Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Single-Dose Efficacy of an Albuterol Breath Activated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered Dose Inhaler (HFA-MDI) (Both Using the Same Hydrofluoroalkane Propellant) in Asthmatics

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. ) Identifier:
First received: September 14, 2007
Last updated: February 3, 2017
Last verified: February 2017
This is a research study designed to compare the single-dose effectiveness of albuterol-HFA-BAI (breath activated inhaler) and albuterol-HFA-MDI (metered dose inhaler) in asthmatics with poor inhaler coordinating abilities. Patients must be 7 to 70 years of age to participate in this study.

Condition Intervention Phase
Drug: Albuterol-HFA-MDI
Drug: Albuterol-HFA-BAI
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • The percent change in the area-under-the-effect curve from test day baseline FEV1 versus time [ Time Frame: Baseline to two hours post dose, Study Days 1 and 2 ]

Secondary Outcome Measures:
  • The maximum percent increase in FEV1 (%) from baseline within the scheduled first 30 minutes of spirometric evaluations post dose [ Time Frame: Baseline to thirty minutes post dose, Study Days 1 and 2 ]
  • The maximum percent increase in FEV1 from baseline over 2 hours [ Time Frame: Baseline to two hours post dose, Study days 1 and 2 ]
  • The area-under-the-effect curve of change in FEV1 from test-day baseline versus time [ Time Frame: Baseline to two hours post dose, Study days 1 and 2 ]

Enrollment: 49
Study Start Date: January 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Albuterol HFA-BAI
Albuterol Hydrofluoroalkane (HFA) Breath-Actuated Inhaler (BAI)
Drug: Albuterol-HFA-BAI
Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
Other Name: Albuterol
Active Comparator: Albuterol HFA-MDI
Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
Drug: Albuterol-HFA-MDI
Inhalation Aerosols, 90 mcg, 1 dose per treatment period
Other Names:
  • Albuterol
  • ProAir


Ages Eligible for Study:   7 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or females aged 7-70 years old
  • Asthma of a minimum of 6 months duration
  • Patients who demonstrate poor inhalation/actuation coordination when evaluated with the AIM -Aerosol Inhalation Monitor.
  • Reversible bronchoconstriction of >12% increase in FEV1 with a cumulative dose of 450 mcg of albuterol
  • The reversibility (FEV1) of <70% following administration of the initial 90 mcg of albuterol
  • Ability to perform spirometry reproducibly
  • Ability to self-perform PEF determinations and report scores on diaries
  • Can tolerate withdrawal of applicable medications at screening
  • Otherwise healthy individuals
  • Non-smokers for at least two years

Exclusion Criteria:

  • Allergy or sensitivity to albuterol
  • Exposure to investigational drugs within 30 days prior to the screening visit
  • Continuous treatment with Beta-blockers, MAO inhibitors, tricyclic antidepressants, and/or systemic corticosteroids
  • Treated with oral or injectable corticosteroids within the six weeks prior to the screening visit
  • Unstable dose regimen of any required antileukotrienes, inhaled corticosteroids and/or inhaled cromolyn and/or nedocromil
  • Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications
  • Hospitalization for acute exacerbation of asthma more than twice in past year
  • Treatment in an emergency room or hospitalization for asthmatic symptoms within three months prior to the screening visit
  • An upper respiratory tract infection and/or sinusitis associated with exacerbation of asthma that is unresolved three weeks prior to the screening visit
  • History and/or presence of any clinically significant non-asthmatic acute or chronic disease
  • Known or suspected substance abuse
  • Previous enrollment in an IVAX Research-sponsored Albuterol HFA asthma study
  • Other criteria apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00530062

United States, California
Clinical Study Site
Huntington Beach, California, United States, 92647
United States, Colorado
Teva Clinical Study Site
Lakewood, Colorado, United States, 80401
United States, Minnesota
Clinical Study Site
Minneapolis, Minnesota, United States, 55402
United States, Oklahoma
Clinical Study Site
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
Clinical Study Site
Lake Oswego, Oregon, United States, 97035
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Study Chair: Clinical Study Leader Teva Branded Pharmaceutical Products, R&D Inc.
  More Information

Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc. Identifier: NCT00530062     History of Changes
Other Study ID Numbers: IXR-404-04-167
Study First Received: September 14, 2007
Last Updated: February 3, 2017

Keywords provided by Teva Pharmaceutical Industries:
Asthma and Poor Coordinators of Asthma Inhalers

Additional relevant MeSH terms:
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 24, 2017